CMO Steve Pakola sold 56,333 shares in 2 transactions for $688,755.82 (avg $12.23); retains 213,009 shares plus 66,973 stock options.
Steve Pakola, Chief Medical Officer at REGENXBIO, executed 2 separate sales totaling 56,333 shares (56.3K shares) for $688,755.82 over two days (June 29 and July 1, 2026), reducing his non-derivative holdings by 20.9% from 269,342 to 213,009 shares. The blended average sale price was $12.23, below the current price of $13.09 and well below the 52-week high of $16.19. This partial sale occurs at a moment when RGNX has posted strong short-term momentum (+83.3% over 30 days, +53.5% over 90 days), yet the company remains unprofitable with a net income of $-90,051,000.00 over its most recent full fiscal year. Pakola retains meaningful equity exposure through 66,973 stock options, indicating he has not fully exited his position.